BB
BBOT
BridgeBio Oncology Therapeutics, Inc.
$7.26
-6.68%
$623.2M
No data for this timeframe.
Vol
Market Cap$623.2M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders7 funds
Inst. Value$17.6M
Inst. Activity4 buys / 0 sells
SEC Reports2
Press Releases4
Recent Activity
May 12, 2026
SEC
BBOT reported Q1 2026 net loss of $42.1M vs $22.1M a year ago, with R&D spend nearly doubling to $39.8M as three clinica
PRESS-RELEASE — Impact 4/10
May 12, 2026
earnings
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
<p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics,
May 10, 2026
Insider
Beltran Pedro sold 1,103,837 shares
President and CEO @ $0.00 ($0.00)
May 10, 2026
Insider
Elmelech Idan sold 758,222 shares
COO & Principal Financial Ofcr @ $0.00 ($0.00)
Apr 21, 2026
Press
BBOT presented new preclinical data for BBO-10203, a first-in-class RAS:PI3Kα breaker, showing tumor regressions and str
Impact 7/10
Apr 20, 2026
Press
BBOT announced that the FDA granted Fast Track designation to its pan-KRAS inhibitor BBO-11818 for advanced KRAS-mutant
Impact 7/10
Apr 1, 2026
Insider
Ben Yong sold 1,047 shares
Chief Med & Dev Officer @ $9.03 ($9.5K)
Mar 5, 2026
SEC
BridgeBio Oncology Therapeutics (BBOT) reported its 2025 financial results and provided a corporate update, highlighting
8-K — Impact 7/10
Price Targets
$25.11
+245.9% upside
Strong Buy
Current $7.26
Low $18.00
Median $23.00
High $41.00
9 analysts
$18.00
$41.00
Analyst Ratings
6Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Canaccord Genuity | INITIATE | Buy |
| Mar 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Feb 11, 2026 | Stifel | INITIATE | Buy |
| Jan 9, 2026 | Raymond James | INITIATE | Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.54 ▼ -3.6% | $-0.67 — $-0.41 | 9 | |
| Next Q | $-0.56 ▼ -4.4% | $-0.71 — $-0.43 | 46% YoY | 8 |
| Current FY | $-2.22 ▼ -7.1% | $-2.72 — $-1.72 | 48% YoY | 9 |
| Next FY | $-2.14 ▼ -4.6% | $-2.46 — $-1.61 | 4% YoY | 8 |
Latest Reports
NEUTRAL
PRESS-RELEASE
4/10
BBOT reported Q1 2026 net loss of $42.1M vs $22.1M a year ago, with R&D spend nearly doubling to $39.8M as three clinica
May 12, 2026
BULLISH
Press
7/10
BBOT presented new preclinical data for BBO-10203, a first-in-class RAS:PI3Kα breaker, showing tumor regressions and str
Apr 21, 2026
BULLISH
8-K
7/10
BridgeBio Oncology Therapeutics (BBOT) reported its 2025 financial results and provided a corporate update, highlighting
Mar 5, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $9.9M | NEW |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $3.5M | NEW |
| FMR LLC | $3.0M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $930.2K | NEW |
| MORGAN STANLEY | $179.7K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 10, 2026 | Beltran Pedro | A | $0.00 |
| May 10, 2026 | Elmelech Idan | A | $0.00 |
| Apr 1, 2026 | Ben Yong | F | $9.5K |
| Apr 1, 2026 | Beltran Pedro | F | $9.5K |
| Apr 1, 2026 | Mehra Uneek | F | $4.7K |
7 institutional holders with $17.6M total value (1,403,383 shares) as of 2025-Q4. Top holders: VANGUARD, CHARLES, FMR. Net buying activity: 4 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 791,095 | $9.9M | 56.4% | NEW |
| 2 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 279,046 | $3.5M | 19.9% | NEW |
| 3 | FMR LLC | 240,300 | $3.0M | 17.1% | ADD +48.3% |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 74,300 | $930.2K | 5.3% | NEW |
| 5 | MORGAN STANLEY | 14,352 | $179.7K | 1.0% | DOUBLED +1566.9% |
| 6 | BANK OF AMERICA CORP /DE/ | 3,990 | $50.0K | 0.3% | DOUBLED +200.2% |
| 7 | WELLS FARGO & COMPANY/MN | 300 | $3.8K | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| FMR LLC | ADD | 162,077 | 240,300 | +48.3% | $3.0M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 74,300 | — | $930.2K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 861 | 14,352 | +1566.9% | $179.7K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,329 | 3,990 | +200.2% | $50.0K | 2025-Q4 |
| VANGUARD GROUP INC | NEW | — | 647,599 | — | $7.5M | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 279,350 | — | $3.2M | 2025-Q3 |
| FMR LLC | NEW | — | 162,077 | — | $1.9M | 2025-Q3 |
| UBS Group AG | NEW | — | 52,226 | — | $604.8K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEW | — | 1,329 | — | $15.4K | 2025-Q3 |
5 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 10, 2026 | Beltran Pedro | President and CEO | A | 1,103,837 | $0.00 | $0.00 |
| May 10, 2026 | Elmelech Idan | COO & Principal Financial Ofcr | A | 758,222 | $0.00 | $0.00 |
| Apr 1, 2026 | Ben Yong | Chief Med & Dev Officer | F | 1,047 | $9.03 | $9.5K |
| Apr 1, 2026 | Beltran Pedro | President and CEO | F | 1,047 | $9.03 | $9.5K |
| Apr 1, 2026 | Mehra Uneek | F | 524 | $9.03 | $4.7K | |
| Mar 24, 2026 | Lebowitz Peter F | Director | A | 63,350 | $0.00 | $0.00 |
| Mar 10, 2026 | Ben Yong | Chief Med & Dev Officer | A | 210,000 | $0.00 | $0.00 |
| Mar 10, 2026 | Ben Yong | Chief Med & Dev Officer | A | 46,670 | $0.00 | $0.00 |
| Mar 10, 2026 | Beltran Pedro | Chief Scientific Officer | A | 46,670 | $0.00 | $0.00 |
| Mar 10, 2026 | Mehra Uneek | Chief Financial Officer | A | 105,000 | $0.00 | $0.00 |
| Mar 10, 2026 | Mehra Uneek | Chief Financial Officer | A | 23,330 | $0.00 | $0.00 |
| Mar 10, 2026 | Beltran Pedro | Chief Scientific Officer | A | 210,000 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
BULLISH
7/10
BBOT presented new preclinical data for BBO-10203, a first-in-class RAS:PI3Kα breaker, showing tumor
Apr 21, 2026
BULLISH
7/10
BBOT announced that the FDA granted Fast Track designation to its pan-KRAS inhibitor BBO-11818 for a
Apr 20, 2026
BULLISH
8/10
BBOT announced preclinical and early clinical data for BBO-11818, a novel panKRAS inhibitor showing
Mar 6, 2026
BULLISH
8/10
BBOT, a clinical-stage oncology company, reported its fourth quarter and full year 2025 financial re
Mar 5, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 6 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$25.11 mean target
+245.9% upside
Strong Buy (1.30)
$18.00 Low
$41.00 High
| Metric | Value |
|---|---|
| Current Price | $7.26 |
| Target Low | $18.00 |
| Target Mean | $25.11 |
| Target Median | $23.00 |
| Target High | $41.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.30) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.54 | $-0.67 | $-0.41 | — | -3.6% | 1↑ 3↓ | $0.0B | — | 9 |
| Next Q 2026-09-30 |
$-0.56 | $-0.71 | $-0.43 | 45.8% | -4.4% | 0↑ 3↓ | $0.0B | 0.0% | 8 |
| Current FY 2026-12-31 |
$-2.22 | $-2.72 | $-1.72 | 48.3% | -7.1% | 0↑ 5↓ | $0.0B | 0.0% | 9 |
| Next FY 2027-12-31 |
$-2.14 | $-2.46 | $-1.61 | 3.7% | -4.6% | 0↑ 4↓ | $0.0B | 0.0% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.539 | |
| 7d ago | $-0.539 | |
| 30d ago | $-0.520 | -0.019 |
| 60d ago | $-0.520 | -0.019 |
| 90d ago | $-0.517 | -0.022 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Canaccord Genuity | INITIATE | — | Buy |
| Mar 6, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 11, 2026 | Stifel | INITIATE | — | Buy |
| Jan 9, 2026 | Raymond James | INITIATE | — | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 6 | 8 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 5 | 8 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
<p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage bio
May 12, 2026
contract
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a cl
May 11, 2026
earnings_calendar
BBOT Q1 2026 Earnings Scheduled — 2026-05-11
May 7, 2026
earnings_calendar
BBOT Q1 2026 Earnings Scheduled — 2026-05-07
Apr 22, 2026
routine
BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026
<p><em>BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibitin
Apr 21, 2026
fda
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
<p><em>BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the
Apr 20, 2026
fda
BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma
<p><em>BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally advanced unresectable or metastatic KRAS-mutan
Apr 17, 2026
short_interest
FTD: BBOT — 103,304 shares ($1.0M) failed to deliver
Settlement: 20260417, Price: $9.22, FTD Value: $952,462.88, BRIDGEBIO ONCOLOGY THERAPEUTIC
Apr 16, 2026
short_interest
FTD: BBOT — 79,362 shares ($0.7M) failed to deliver
Settlement: 20260416, Price: $9.39, FTD Value: $745,209.18, BRIDGEBIO ONCOLOGY THERAPEUTIC
Apr 13, 2026
other
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Mar 18, 2026
routine
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
<p align="left">SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a cli
Mar 6, 2026
announcement
BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor
<p align="center"><em>BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high s
Mar 5, 2026
earnings
BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
<p align="justify">SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a
Mar 3, 2026
earnings_calendar
BBOT Q4 2025 Earnings Scheduled — 2026-03-03
Mar 3, 2026
short_interest
FTD: BBOT — 339,194 shares ($3.4M) failed to deliver
Settlement: 20260303, Price: $10.08, FTD Value: $3,419,075.52, BRIDGEBIO ONCOLOGY THERAPEUTIC